GlassScriptPhysician profile
Katie A Smith
NPI 1154827335
$501.50
in general payments reported to CMS, 2019-2025
12 companies · $97.05 in 2025
The $97.05 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.67 · 2021: $68.52 · 2022: $134 · 2023: $104 · 2024: $80.52 · 2025: $97.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $281.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $97.93 | 2022-2024 | Shingrix, Boostrix |
| Tarsus Pharmaceuticals, INC. | $97.05 | 2025 | Xdemvy |
| Pfizer INC. | $76.31 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.52 | 2022-2023 | Synjardy, Jardiance |
| Exact Sciences Corporation | $40.32 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $24.08 | 2023 | Freestyle Libre 2 |
| Novo Nordisk INC | $20.00 | 2024 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $19.91 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.18 | 2022 | |
| Biogen, INC. | $17.67 | 2020 | |
| Gilead Sciences, INC. | $15.66 | 2021 | |
| Dynavax Technologies Corporation | $14.87 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.